Table 3. Univariate and multivariate analyses of overall survival.
| Characteristic | Univariate analysis | Multivariate Cox regression analysis | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
| Age | 1.135 (0.813–1.583) | 0.457 | |||
| Histological type | 2.171 (1.173–4.020) | 0.014* | 1.756 (0.942–3.272) | 0.076 | |
| T stage | 1.864 (1.559–2.227) | <0.001* | 1.149 (0.918–1.437) | 0.226 | |
| N stage | 2.294 (1.981–2.655) | <0.001* | 2.104 (1.713–2.394) | <0.001* | |
| M stage | 7.983 (4.499–14.166) | <0.001* | 4.221 (2.275–7.834) | <0.001* | |
| pTNM stage | 3.574 (2.833–4.509) | <0.001* | |||
| ER | 0.598 (0.426–0.838) | 0.003* | 0.764 (0.457–1.279) | 0.306 | |
| PR | 0.543 (0.389–0.757) | <0.001* | 0.813 (0.491–1.346) | 0.421 | |
| HER2 | 1.795 (1.281–2.516) | 0.001* | 1.274 (0.878–1.848) | 0.203 | |
| Ki-67 | 2.116 (1.413–3.169) | <0.001* | 1.515 (0.990–2.320) | 0.056 | |
| Molecular subtype | 1.224 (1.093–1.370) | <0.001* | |||
| CEA | 3.157 (2.093–4.762) | <0.001* | 1.341 (0.841–2.137) | 0.218 | |
| CA153 | 1.901 (1.247–2.899) | 0.003* | 0.865 (0.539–1.390) | 0.550 | |
| CONUT | 1.502 (1.043–2.162) | 0.029* | 1.465 (1.007–2.132) | 0.046* | |
*P<0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; CEA, carcinoembryonic antigen; CA153, cancer antigen 153.